Last reviewed · How we verify
MINI CHEP
MINI CHEP is a chemotherapy regimen combining mini-dose chemotherapy agents designed to treat acute leukemia with reduced toxicity.
MINI CHEP is a chemotherapy regimen combining mini-dose chemotherapy agents designed to treat acute leukemia with reduced toxicity. Used for Acute leukemia (elderly or unfit patients).
At a glance
| Generic name | MINI CHEP |
|---|---|
| Sponsor | French Innovative Leukemia Organisation |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MINI CHEP appears to be a modified chemotherapy protocol for leukemia that uses lower doses of conventional chemotherapy agents to improve tolerability while maintaining efficacy. This approach is particularly relevant for elderly or frail patients who may not tolerate standard-intensity chemotherapy regimens.
Approved indications
- Acute leukemia (elderly or unfit patients)
Common side effects
- Myelosuppression
- Infection
- Anemia
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MINI CHEP CI brief — competitive landscape report
- MINI CHEP updates RSS · CI watch RSS
- French Innovative Leukemia Organisation portfolio CI